Sai Life Sciences Limited has informed the Exchange regarding "Reply to SES on recommendation of Postal Ballot Notice (under of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 ''.

Sai Life Sciences has formally responded to proxy advisory firm Stakeholders Empowerment Services (SES), which had recommended that shareholders vote AGAINST two sets of resolutions in the company's postal ballot dated May 15, 2025. The first set relates to ratification of ESOP Schemes 2008 and 2018 and their extension to employees of subsidiary and group companies; the second is the appointment of Dr. Dinesh V Patel as an Independent Director. On the ESOP issue, the company clarified that the NRC's discretion on exercise price is permitted under SEBI rules, that grants have historically been priced at or above Rs. 1,273 (the price paid by a PE investor), and that any grant exceeding 1% of capital to a single employee in a year will need fresh shareholder approval. On Dr. Patel, the company noted his shareholding of about 0.2% is well below the 2% legal threshold for independence, and that the NRC and Board have already satisfied themselves on his independence. SES had flagged a potential benefit of up to Rs. 56.87 Crores to a single employee under the ESOP plans.